AU2019445762A1 - Eltrombopag dosing regimen - Google Patents

Eltrombopag dosing regimen Download PDF

Info

Publication number
AU2019445762A1
AU2019445762A1 AU2019445762A AU2019445762A AU2019445762A1 AU 2019445762 A1 AU2019445762 A1 AU 2019445762A1 AU 2019445762 A AU2019445762 A AU 2019445762A AU 2019445762 A AU2019445762 A AU 2019445762A AU 2019445762 A1 AU2019445762 A1 AU 2019445762A1
Authority
AU
Australia
Prior art keywords
eltrombopag
tapering
dose
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019445762A
Other languages
English (en)
Inventor
Nichola COOPER
Waleed GHANIMA
Miona STANKOVIC
Francesco ZAJA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2019445762A1 publication Critical patent/AU2019445762A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: NOVARTIS PHARMACEUTICALS CORPORATION
Priority to AU2023274065A priority Critical patent/AU2023274065A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019445762A 2019-05-14 2019-05-14 Eltrombopag dosing regimen Abandoned AU2019445762A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023274065A AU2023274065A1 (en) 2019-05-14 2023-11-27 Eltrombopag dosing regimen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/032171 WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023274065A Division AU2023274065A1 (en) 2019-05-14 2023-11-27 Eltrombopag dosing regimen

Publications (1)

Publication Number Publication Date
AU2019445762A1 true AU2019445762A1 (en) 2021-12-09

Family

ID=67211802

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019445762A Abandoned AU2019445762A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen
AU2023274065A Abandoned AU2023274065A1 (en) 2019-05-14 2023-11-27 Eltrombopag dosing regimen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023274065A Abandoned AU2023274065A1 (en) 2019-05-14 2023-11-27 Eltrombopag dosing regimen

Country Status (9)

Country Link
US (1) US20220313663A1 (cg-RX-API-DMAC7.html)
EP (1) EP3968984A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537883A (cg-RX-API-DMAC7.html)
KR (1) KR20220035036A (cg-RX-API-DMAC7.html)
AU (2) AU2019445762A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140137A1 (cg-RX-API-DMAC7.html)
IL (1) IL288078A (cg-RX-API-DMAC7.html)
MX (1) MX2021013971A (cg-RX-API-DMAC7.html)
WO (1) WO2020231407A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201406373A (zh) * 2012-06-29 2014-02-16 Shionogi & Co 含有具有血栓形成素受體促效作用之化合物之醫藥組合物

Also Published As

Publication number Publication date
JP2023182667A (ja) 2023-12-26
MX2021013971A (es) 2022-04-01
AU2023274065A1 (en) 2023-12-14
JP2022537883A (ja) 2022-08-31
US20220313663A1 (en) 2022-10-06
IL288078A (en) 2025-01-01
CA3140137A1 (en) 2020-11-19
WO2020231407A1 (en) 2020-11-19
KR20220035036A (ko) 2022-03-21
EP3968984A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP7295305B2 (ja) ループス腎炎の治療のための改善されたプロトコル
TWI786636B (zh) 用於治療葡萄膜炎及黃斑水腫之包含il6r抗體的組合物與其使用方法
JP2024530954A5 (cg-RX-API-DMAC7.html)
Schiappapietra et al. Glucocorticoids in juvenile idiopathic arthritis
Desideri et al. Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage
US9920131B2 (en) Dosage and administration of anti-EGFR therapeutics
WO2020231408A1 (en) Eltrombopag dosing regimen
JP2021152002A5 (cg-RX-API-DMAC7.html)
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
AU2023274065A1 (en) Eltrombopag dosing regimen
JP2018505901A (ja) 統合失調症の治療のためのイロペリドン
Spies et al. Analyses of similarities and differences in glucocorticoid therapy between rheumatoid arthritis and ankylosing spondylitis—a systematic comparison
JP2024516886A5 (cg-RX-API-DMAC7.html)
McNeil Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity
JP2020172471A (ja) ヒト化抗ヒトcd26抗体を含有する医薬組成物
Delaney et al. Emerging treatments for non-infectious uveitis
RU2023120407A (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r
Dalton et al. Ranibizumab achieves higher BCVA gains for BRVO in COMRADE-B.
RU2024105814A (ru) Лечение атопического дерматита
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf
WO2019231800A1 (en) Anti-cgrp antibodies for treating menstrual-related migraines
Narayanan et al. Corticosteroids: Triamcinolone, Dexamethasone
INGERMAN et al. Emerging Treatments

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOVARTIS AG

Free format text: FORMER APPLICANT(S): NOVARTIS PHARMACEUTICALS CORPORATION

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted